Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.

NCT00987493 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00987493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00987493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2009
Completion date
April 30, 2016
Enrollment
49 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma